Comparative analysis of anticholinergic burden scales to explain iatrogenic cognitive impairment in schizophrenia: results from the multicenter FACE-SZ cohort DOI Creative Commons
Nathan Vidal, Paul Roux,

Mathieu Urbach

и другие.

Frontiers in Pharmacology, Год журнала: 2024, Номер 15

Опубликована: Июнь 12, 2024

Aim The anticholinergic properties of medications are associated with poorer cognitive performance in schizophrenia. Numerous scales have been developed to assess burden and yet, there is no consensus indicating which scale more relevant for patients We aimed identify valid estimating the risk iatrogenic impairment Methods identified 27 a literature review. responses neuropsychological tests 839 individuals schizophrenia or schizoaffective disorder FACE-SZ database were collected between 2010 2021. estimated association objective global scales, number psychotropic drugs, chlorpromazine lorazepam equivalents bivariable regressions cross-sectional design. then adjusted models covariates: predictors significantly multiple linear considered good concurrent validity performance. Results Eight drug impairment. most convenient predictor compute, was worse executive function (Standardized β = −0.12, p .004) reasoning −0.08, .037). Conclusion Anticholinergic burden, weakly cognition, thus suggesting that explained by factors other than medication. drugs parsimonious method

Язык: Английский

Pneumonia Risk, Antipsychotic Dosing, and Anticholinergic Burden in Schizophrenia DOI
Jurjen J. Luykx, Christoph U. Correll,

Peter Manu

и другие.

JAMA Psychiatry, Год журнала: 2024, Номер 81(10), С. 967 - 967

Опубликована: Июнь 26, 2024

Importance Antipsychotic drugs (particularly clozapine) have been associated with pneumonia in observational studies. Despite studies of the associations between antipsychotic use and incident pneumonia, it remains unclear to what degree is increased risk whether dose-response exist, agents are specifically pneumonia. Objective To estimate specific antipsychotics examine polytherapy, dosing, receptor binding properties patients schizophrenia. Design, Setting, Participants This cohort study identified schizophrenia or schizoaffective disorder (hereafter, schizophrenia) aged 16 years older from nationwide Finnish registers 1972 2014. Data on diagnoses, inpatient care, specialized outpatient care were obtained Hospital Discharge Register. Information medication dispensing was Prescription Study follow-up 1996 2017. analyzed November 4, 2022, December 5, 2023. Exposures Use monotherapies; modeled by dosage as low (<0.6 World Health Organization defined daily dose [DDD] per day), medium (0.6 <1.1 DDDs high (≥1.1 day); polypharmacy; categorized according their anticholinergic burden low, medium, high. Main Outcomes Measures The primary outcome hospitalization for Pneumonia using adjusted, within-individual Cox proportional hazards regression models, no reference. Results included 61 889 persons (mean [SD] age, 46.2 [16.0] years; 31 104 men [50.3%]). During 22 follow-up, 8917 (14.4%) had 1 more hospitalizations 1137 (12.8%) died within 30 days admission. Compared use, any overall not (adjusted hazard ratio [AHR], 1.12; 95% CI, 0.99-1.26). Monotherapy compared (AHR, 1.15 [95% 1.02-1.30]; P = .03) a dose-dependent manner, but polytherapy not. When burden, only 1.26 1.10-1.45]; < .001). Of drugs, high-dose quetiapine 1.78 1.22-2.60]; .003), high- medium-dose clozapine 1.44 1.22-1.71]; .001 AHR, 1.43 1.18-1.74]; .001, respectively), olanzapine 1.29 1.05-1.58]; .02) risk. Conclusions Relevance this suggest that schizophrenia, include (at dosages ≥180 mg/d) also (≥440 (≥11 mg/d). Moreover, monotherapy manner. These findings call prevention strategies aimed at requiring high-risk antipsychotics.

Язык: Английский

Процитировано

14
The Prognostic Utility of Anticholinergic Burden Scales: An Integrative Review and Gap Analysis DOI
Henry Ukachukwu Michael, Okechukwu Harrison Enechukwu, Marie‐Josée Brouillette

и другие.

Drugs & Aging, Год журнала: 2023, Номер 40(9), С. 763 - 783

Опубликована: Июль 18, 2023

Язык: Английский

Процитировано

11
Polypharmacy and anticholinergic burden scales in older adults: a cross-sectional study among psychiatric outpatients in a tertiary care hospital DOI Creative Commons
Manjunath Bidarolli, Biswadeep Das, Vikram Singh Rawat

и другие.

BMC Geriatrics, Год журнала: 2025, Номер 25(1)

Опубликована: Янв. 20, 2025

Mental disorders are prevalent among older adults, often leading to the use of multiple medications, many with anticholinergic properties. Polypharmacy, common in this population, is a major contributor burden, which linked cognitive and physical decline. This study investigates relationship between polypharmacy burden across seven scales elderly patients attending psychiatric outpatient. Study was conducted at psychiatry outpatient clinic All India Institute Medical Sciences, Rishikesh, India, from December 2021 March 2023. Elderly (aged ≥ 60 years) who were on least one psychotropic medication had primary working diagnosis illness included. including antidepressants, antipsychotics, mood stabilizers, hypnotics, evaluated. Anticholinergic calculated by respective tools. Univariate analysis adopted determine factors that may affect polypharmacy. included 1165 aged years. The prevalence 20.43% (n = 238). Clonazepam 364, 17.28%), escitalopram 197, 9.35%), metformin 165, 7.83%), sertraline 141, 6.69%), mirtazapine 129, 6.12%), lorazepam 110, 5.22%) most frequently prescribed drugs. demonstrated all risk assessment closely correlated polypharmacy, strongest association observed for Load Scale (ALS) (Odds Ratio 4.3; p < 0.001). Polypharmacy also positively associated adverse drug reactions 1.81; 95% Confidence Interval 1.27–2.56). cohort high, 95.1% 1108) experiencing significant burden. Adverse events stronger correlation ALS scores than other adults.

Язык: Английский

Процитировано

0
Anticholinergic drug exposure is associated with prevalence, worsening and incidence of dysphagia among hospitalized older adults DOI Creative Commons
Lucia Muglia, Alessia Beccacece, Luca Soraci

и другие.

The journal of nutrition health & aging, Год журнала: 2025, Номер 29(5), С. 100507 - 100507

Опубликована: Фев. 13, 2025

Язык: Английский

Процитировано

0
Pharmacotherapy for overactive bladder syndrome and the risk of incident dementia DOI
David Sheyn, Jennifer Murphy, Abhimanyu Mahajan

и другие.

World Journal of Urology, Год журнала: 2025, Номер 43(1)

Опубликована: Апрель 4, 2025

Язык: Английский

Процитировано

0
Comparison of Anticholinergic Burden Scales and Their Association with Cognitive and Functional Impairment in Older Adults: A Cross-Sectional Study Using the REPOSI Database DOI
Alessio Novella, Marina Azab, Luca Pasina

и другие.

Drugs & Aging, Год журнала: 2025, Номер unknown

Опубликована: Апрель 15, 2025

Язык: Английский

Процитировано

0
Subjective Memory Complaints in Older Adults: The Role of Polypharmacy and Anticholinergic Burden DOI
Betül Gülsüm Yavuz Veizi,

Ekin Oktay Oğuz,

Mehmet İlkin Naharcı

и другие.

Journal of Geriatric Psychiatry and Neurology, Год журнала: 2025, Номер unknown

Опубликована: Май 1, 2025

BackgroundSubjective memory complaints (SMC) are common in older adults and may indicate an increased risk of cognitive decline. Polypharmacy anticholinergic burden have been associated with impairment, but their specific contribution to SMC remains unclear. The aim this study was investigate the association between polypharmacy, community-dwelling adults.MethodsThis cross-sectional included 652 participants aged 65 years from geriatric outpatient clinics. assessed via a structured clinician-administered question, function evaluated using Mini-Mental State Examination (MMSE). defined as concomitant use five or more medications, while determined Anticholinergic Burden Classification (ABC). Logistic regression models were used examine independent effects polypharmacy on SMC, adjusting for demographic variables, comorbidities depressive symptoms.ResultsSMC reported by 48% participants. (OR = 2.10, 95% CI: 1.43-3.08, P < 0.001) higher 2.39, 1.72-3.32, independently SMC. Chronic obstructive pulmonary disease (COPD) also identified significant predictor 2.90, 1.41-5.98, 0.004).ConclusionPolypharmacy factors adults. Reducing unnecessary medication minimizing help alleviate complaints. Future longitudinal studies needed determine causal relationships possible interventions.

Язык: Английский

Процитировано

0
Ageing-related considerations for medication used in supportive care in cancer DOI
Darren J. Walsh, Michelle O’Driscoll, Laura J. Sahm

и другие.

Journal of Geriatric Oncology, Год журнала: 2024, Номер 15(5), С. 101760 - 101760

Опубликована: Март 30, 2024

Язык: Английский

Процитировано

3
The predictive value of anticholinergic drug exposure and the outcome of pneumonia: a Danish database study DOI
Yuki Yoshimatsu, Kristian Kragholm, Silas Zacharias Clemmensen

и другие.

Age and Ageing, Год журнала: 2024, Номер 53(2)

Опубликована: Янв. 25, 2024

Older adults are susceptible to anticholinergic effects. Dysphagia and pneumonia associated with usage, though a definitive causative relationship has not been established. There is no effective way predict the prognosis of older pneumonia; therefore, this study investigates predictive value burden.

Язык: Английский

Процитировано

2
Development of the Swedish anticholinergic burden scale (Swe-ABS) DOI Creative Commons
Tanja Rube,

Astrid Ecorcheville,

Elisabet Londos

и другие.

BMC Geriatrics, Год журнала: 2023, Номер 23(1)

Опубликована: Авг. 25, 2023

Abstract Background Drugs with anticholinergic properties are associated cognitive adverse effects, especially in patients vulnerable to central muscarinic antagonism. A variety of drugs show weak, moderate or strong effects. Therefore, the cumulative burden should be considered impairment. This study aimed develop a Swedish Anticholinergic Burden Scale (Swe-ABS) used health care and research. Methods systematic literature review was conducted PubMed Ovid Embase identify previously published tools quantifying drug (i.e., exposure). grading scores (0–3, no high activity) were extracted from identified lists. Enteral parenteral authorized Sweden included. conflicting existing lists assessed by an expert group. Two that not also added evaluation process. Results The search following nine scales: Activity Scale, Classification, updated Cognitive scale, Drug Load Risk Clinician-rated German Korean Scale. list significant effects provided National Board Health Welfare included suggested Swe-ABS consists 104 scored as having hundred fifty-six listed based on previous scales. In total, 62 Conclusions is simplified method quantify easy use clinical practice. Publication this scale might make clinicians more aware patients’ total burden. Further research needed validate evaluate exposure versus clinically outcomes.

Язык: Английский

Процитировано

5